Therapy Area topics
Cardiovascular
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Diabetes prevention signal emerges for Farxiga
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Central Nervous System
Zynerba fragile after pivotal failure
The implosion of Zygel’s fragile X study leaves its developer few places to turn.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Diabetes
Akero continues to pull ahead of Nash rivals
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
Diabetes prevention signal emerges for Farxiga
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Inventiva gets a surprise hit in Nash
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
Digital Health
Philips sells the household goods and could spend on tech instead
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Oncology
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Tisotumab’s cervical cancer efficacy falls off
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.
Respiratory
The scramble to reinvent the ventilator
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Various
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
